Shimauchi Takatoshi, Sugita Kazunari, Nishio Daisuke, Isoda Hideka, Abe Shoko, Yamada Yoko, Hino Ryosuke, Ogata Makiko, Kabashima Kenji, Tokura Yoshiki
Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyusyu 807-8555, Japan.
J Dermatol Sci. 2008 Jun;50(3):217-25. doi: 10.1016/j.jdermsci.2007.12.004. Epub 2008 Feb 19.
Mycosis fungoides (MF) is a T cell neoplasm with elevation of serum Th2 chemokines. Although interferon-gamma (IFN-gamma) administration and narrowband-UVB (NB-UVB) phototherapy are used for the treatment of MF, a combination therapy of these two modalities is not fully established.
To define whether the combination of IFN-gamma and NB-UVB affects the balance of serum levels of Th1 and Th2 chemokines in patients with MF.
Twelve patients with MF received intravenous or intramuscular injections of recombinant IFN-gamma (rIFN-gamma) or natural IFN-gamma (nIFN-gamma) in combination with NB-UVB phototherapy. As control, three MF patients were treated with NB-UVB monotherapy. At the beginning and cessation of therapy, the concentrations of serum Th2 chemokines, TARC/CCL17 and MDC/CCL22, and Th1 chemokines, IP-10/CXCL10 and MIG/CXCL9 were measured by ELISA.
Before treatment, not only Th2 chemokines but also Th1 chemokines were elevated in the patients. Whereas no significant changes were observed in the levels of TARC and MDC, IP-10 and MIG were further elevated by the combination of IFN-gamma and NB-UVB. On the other hand, NB-UVB monotherapy did not change the level of either Th1 or Th2 chemokine.
The combination of IFN-gamma and NB-UVB elevated serum Th1 chemokines but unaffected Th2 chemokines. Since NB-UVB monotherapy could not affect the chemokine levels, the effect of the combination therapy is attributable to IFN-gamma. Given the role of Th1 chemokines for tumor-attacking T cell recruitment at the early stage of MF, the therapy may exert a beneficial effect for early MF.
蕈样肉芽肿(MF)是一种血清Th2趋化因子升高的T细胞肿瘤。尽管干扰素-γ(IFN-γ)给药和窄谱中波紫外线(NB-UVB)光疗用于MF的治疗,但这两种方式的联合治疗尚未完全确立。
确定IFN-γ与NB-UVB联合使用是否会影响MF患者血清中Th1和Th2趋化因子水平的平衡。
12例MF患者接受重组IFN-γ(rIFN-γ)或天然IFN-γ(nIFN-γ)静脉或肌肉注射,并联合NB-UVB光疗。作为对照,3例MF患者接受NB-UVB单一疗法治疗。在治疗开始和结束时,通过酶联免疫吸附测定法(ELISA)测量血清Th2趋化因子TARC/CCL17和MDC/CCL22以及Th1趋化因子IP-10/CXCL10和MIG/CXCL9的浓度。
治疗前,患者不仅Th2趋化因子升高,Th1趋化因子也升高。虽然TARC和MDC水平未观察到显著变化,但IFN-γ与NB-UVB联合使用使IP-10和MIG进一步升高。另一方面,NB-UVB单一疗法未改变Th1或Th2趋化因子的水平。
IFN-γ与NB-UVB联合使用可升高血清Th1趋化因子,但不影响Th2趋化因子。由于NB-UVB单一疗法不能影响趋化因子水平,联合治疗的效果归因于IFN-γ。鉴于Th1趋化因子在MF早期对肿瘤攻击T细胞募集的作用,该疗法可能对早期MF发挥有益作用。